{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:50:15Z","timestamp":1790812215035,"version":"4.1.0"},"reference-count":18,"publisher":"Jaypee Brothers Medical Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.59556\/japi.73.1093","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:54:54Z","timestamp":1760421294000},"page":"85-90","source":"Crossref","is-referenced-by-count":3,"title":["Introducing a Novel Once-weekly Dipeptidyl Peptidase 4 Inhibitor: Trelagliptin in India"],"prefix":"10.59556","volume":"73","author":[{"given":"Bhupesh","family":"Dewan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjaykumar","family":"Navale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddheshwar","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishima","family":"Ganiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20251014055446_B1","unstructured":"World Health Organization. Diabetes in India. Available at: https:\/\/www.who.int\/india\/diabetes last accessed on 21st April 2025"},{"issue":"(10):","key":"key20251014055446_B2","doi-asserted-by":"crossref","first-page":"524.","DOI":"10.4066\/AMJ.2013.1791","article-title":"India towards diabetes control: key issues.","volume":"6","author":"Kumar","year":"2013;","journal-title":"Australas Med J"},{"issue":"(16):","key":"key20251014055446_B3","doi-asserted-by":"crossref","first-page":"8393.","DOI":"10.3390\/ijms22168393","article-title":"The role of glycemic variability in cardiovascular disorders.","volume":"22","author":"Alfieri","year":"2021;","journal-title":"Int J Mol Sci"},{"issue":"(1):","key":"key20251014055446_B4","doi-asserted-by":"crossref","first-page":"145.","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus.","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022;","journal-title":"J Clin Med"},{"key":"key20251014055446_B5","doi-asserted-by":"crossref","first-page":"1775\u2013","DOI":"10.1007\/s13300-018-0488-z","article-title":"Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: an updated review and challenging clinical scenarios.","volume":"9:","author":"Gomez-Peralta","year":"2018;","journal-title":"Diabetes Ther"},{"issue":"(1):","key":"key20251014055446_B6","first-page":"806979.","article-title":"The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: A \u201cme too\u201d or \u201cthe special one\u201d antidiabetic class?","volume":"2015","author":"Godinho","year":"2015;","journal-title":"J Diabetes Res"},{"issue":"(6).","key":"key20251014055446_B7","article-title":"Factors influencing poor medication adherence amongst patients with chronic disease in low- and-middle-income countries: a systematic scoping review.","volume":"8","author":"Chauke","year":"2022;","journal-title":"Heliyon"},{"key":"key20251014055446_B8","doi-asserted-by":"crossref","first-page":"175\u2013","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes.","volume":"4:","author":"Garc\u00eda-P\u00e9rez","year":"2013;","journal-title":"Diabetes Ther"},{"issue":"(10):","key":"key20251014055446_B9","doi-asserted-by":"crossref","first-page":"1161\u2013","DOI":"10.1007\/s40265-015-0431-9","article-title":"Trelagliptin: first global approval.","volume":"75","author":"McKeage","year":"2015;","journal-title":"Drugs"},{"issue":"(6):","key":"key20251014055446_B10","doi-asserted-by":"crossref","first-page":"e0157509.","DOI":"10.1371\/journal.pone.0157509","article-title":"Trelagliptin (SYR-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism.","volume":"11","author":"Grimshaw","year":"2016;","journal-title":"PLoS One"},{"issue":"(1):","key":"key20251014055446_B11","doi-asserted-by":"crossref","first-page":"13296.","DOI":"10.1038\/s41598-019-49803-9","article-title":"Effect of DPP-IV inhibitors on glycemic variability in patients with T2DM: a systematic review and meta-analysis.","volume":"9","author":"Lee","year":"2019;","journal-title":"Sci Rep"},{"key":"key20251014055446_B12","doi-asserted-by":"crossref","first-page":"125\u2013","DOI":"10.1016\/S2213-8587(13)70149-9","article-title":"SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.","volume":"2:","author":"Inagaki","year":"2014;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(5):","key":"key20251014055446_B13","doi-asserted-by":"crossref","first-page":"718\u2013","DOI":"10.1111\/jdi.12499","article-title":"Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: a 52-week open-label, phase 3 study.","volume":"7","author":"Inagaki","year":"2016;","journal-title":"J Diabetes Investig"},{"issue":"(2):","key":"key20251014055446_B14","doi-asserted-by":"crossref","first-page":"373\u2013","DOI":"10.1111\/jdi.13126","article-title":"Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: results from a randomized, phase 3 study.","volume":"11","author":"Kaku","year":"2020;","journal-title":"J Diabetes Investig"},{"issue":"(10):","key":"key20251014055446_B15","doi-asserted-by":"crossref","first-page":"2490\u2013","DOI":"10.1111\/dom.13397","article-title":"Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: results from a randomized, phase IV study.","volume":"20","author":"Kaku","year":"2018;","journal-title":"Diabetes Obes Metab"},{"key":"key20251014055446_B16","doi-asserted-by":"crossref","first-page":"389.","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors.","volume":"10:","author":"Gallwitz","year":"2019;","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"(5):","key":"key20251014055446_B17","first-page":"627\u2013","article-title":"Weekend therapy in diabetes.","volume":"66","author":"Kalra","year":"2016;","journal-title":"J Pak Med Assoc"},{"issue":"(19):","key":"key20251014055446_B18","doi-asserted-by":"crossref","first-page":"2563\u2013","DOI":"10.2169\/internalmedicine.8184-16","article-title":"Efficacy and patient satisfaction of the weekly DPP-4 inhibitors trelagliptin and omarigliptin in 80 Japanese patients with type 2 diabetes.","volume":"56","author":"Tosaki","year":"2017;","journal-title":"Intern Med"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:54:56Z","timestamp":1760421296000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-73-8-85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.59556\/japi.73.1093"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.1093","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}